BMC Clinical Pharmacology

Table 2 Risk of UGIB and perforation associated with aspirin use

From: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

	All cases	Controls	Adjusted RR^*
	(N=2,105)	(N=11,500)	(95%CI)
Non-use	1,696	10,157	1 (reference)
Current use (1-30)	287	837	2.0 (1.7-2.3)
*Use within 1-7*	259	771	2.0 (1.7-2.3)
*days time window*
*Use within 8-30*	28	66	2.3 (1.4-3.7)
*days time window*
Recent use (31-180)	37	123	1.5 (1.0-2.3)
*Use within 31-60*	14	45	1.7 (0.9-3.3)
*days time window*
*Use within 61-180*	23	78	1.5 (0.9-2.5)
*days time window*
Past use (>180)	85	383	1.1 (0.8-1.4)

^* Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.

Back to article page